EUVIMEDEUVIMED entdecken
Open Access

Increasing Use of Germline Genetic Testing in Pancreatic Ductal Adenocarcinoma and Relationship to Clinical Outcome: A Single-Institution Study

Thomas N O'Connor iD, Emily Schultz iD, Michael Horowitz, Margaret H Alexander iD, Christos Fountzilas, Leonid Cherkassky, Kenan Onel iD, Erik S Knudsen iD, Agnieszka K Witkiewicz

JCO Precision Oncology · 2026-04 · 10 (4)

DOI: 10.1200/po-25-01088 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2026-04. Verfasst von Thomas N O'Connor und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Genetic Testing, Germ-Line Mutation. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Precision therapies have improved outcomes in pancreatic ductal adenocarcinoma (PDAC) and highlight the utility of germline genetic testing (GGT) in clinical decision making. Here, we investigate the association of GGT of individuals diagnosed with PDAC over time to identify changes in testing patterns and the relationship of testing with clinicopathologic parameters and overall survival (OS). METHODS The frequency of GGT of 979 patients with PDAC treated at the Roswell Park Comprehensive Cancer Center (RPCCC) between 2017 and 2024 was determined. Factors associated with performing testing and having a germline pathogenic variant (GPV) were assessed. OS and the impact of precision treatment were evaluated. RESULTS Patients with PDAC being treated at RPCCC that had GGT increased from 16.5% in 2017 to 57.6% in 2024. Patients with testing had improved OS compared with patients who did not (HR, 0.46). Individuals of older age, without a personal history of other cancers, without a family history of pancreatic cancer, with advanced disease, and with poorly differentiated tumors were less likely to have testing performed. Individuals with a personal history of other cancers were more likely to have a GPV. Of the 425 patients diagnosed with PDAC that had testing, 58 (13.6%) had a GPV detected. Of patients with testing, 12 had actionable mutations in BRCA1/2 , seven of whom were subsequently treated with olaparib. Three patients harbored actionable mutations in MSH6 , with one patient subsequently treated with pembrolizumab. Patients who received therapy informed by testing results had improved OS (HR, 0.09). CONCLUSION GGT prevalence has increased at RPCCC and informed treatment decisions. Universal point-of-care testing is being implemented with the goal of completing testing for all patients with PDAC seen at RPCCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsGenetic TestingGerm-Line MutationHumansFemaleMaleAgedMiddle Aged

Autor:innen und Institutionen

  • Department of Molecular and Cellular Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
  • Jacobs School of Medicine, University at Buffalo, Buffalo, NY.
  • Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
  • Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
  • Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY.

ORCID-Profile: Thomas N O'Connor, Emily Schultz, Margaret H Alexander, Kenan Onel, Erik S Knudsen

Förderung

  • NCI NIH HHS

Zitieren

APA

O'Connor, T. N., Schultz, E., Horowitz, M., Alexander, M. H., Fountzilas, C., Cherkassky, L., Onel, K., Knudsen, E. S., & Witkiewicz, A. K. (2026). Increasing Use of Germline Genetic Testing in Pancreatic Ductal Adenocarcinoma and Relationship to Clinical Outcome: A Single-Institution Study. JCO Precision Oncology, 10(4). https://doi.org/10.1200/po-25-01088

Vancouver

O'Connor TN, Schultz E, Horowitz M, Alexander MH, Fountzilas C, Cherkassky L, et al. Increasing Use of Germline Genetic Testing in Pancreatic Ductal Adenocarcinoma and Relationship to Clinical Outcome: A Single-Institution Study. JCO Precision Oncology. 2026;10(4). doi:10.1200/po-25-01088

BibTeX
@article{OConnor2026,
  author = {O'Connor, Thomas N and Schultz, Emily and Horowitz, Michael and Alexander, Margaret H and Fountzilas, Christos and Cherkassky, Leonid and Onel, Kenan and Knudsen, Erik S and Witkiewicz, Agnieszka K},
  title = {Increasing Use of Germline Genetic Testing in Pancreatic Ductal Adenocarcinoma and Relationship to Clinical Outcome: A Single-Institution Study},
  journal = {JCO Precision Oncology},
  year = {2026},
  volume = {10},
  number = {4},
  doi = {10.1200/po-25-01088}
}
Kostenlos starten →